Collective Minds

Hem
Sverige
Danderyd
Collective Minds

Ring Vägbeskrivning Webbplats Kontakta praktiken

Imaging in Clinical Trials Solved

05/11/2026

Something new is coming. Stay tuned.

04/11/2026

In oncology trials, one reader's call on one scan can move a patient off a study drug and shift the headline result.

Take progression-free survival: whether a new lesion counts as progression, how a confirmation scan is scheduled, how pseudoprogression is handled in immunotherapy trials. If the imaging charter leaves any of that open, two readers can reach different conclusions from the same images.

Three things tend to decide whether the endpoint holds: response criteria chosen for what the therapy actually does (RECIST 1.1, iRECIST, PERCIST, Lugano), acquisition standardized across sites before the first patient is scanned, and a quality gate at intake, while a bad scan can still be repeated.

Our guide to building reliable oncology imaging endpoints, from the charter to the final analysis: https://eu1.hubs.ly/H0zBCh50

02/11/2026

Outsourcing the imaging in your trial? Three questions worth asking any partner:

1. Who reads the scans, and how are readers qualified?
2. How is image quality checked before it reaches the reader?
3. What happens when two readers disagree?

We are at OCT DACH in Basel today and tomorrow, booth 14. Come say hello:
Pär Kragsterman, Co-founder & CTO
Matias Rodriguez, Head of Sales & Marketing
Sverre Bengtsson, VP Clinical Trial Solutions
Habib ElSherif, Business Development Manager

29/10/2026

Stroke care relies on timely assessment, clinical expertise, and medical imaging to help healthcare professionals understand what is happening in the brain and guide clinical decisions.

But the impact of imaging extends beyond individual patient assessments. It also creates opportunities to deepen medical knowledge, strengthen research, and advance our understanding of stroke.

At Collective Minds, we believe that connecting medical imaging, clinical expertise, and research communities can help break down barriers to collaboration and enable new opportunities for medical research.

By supporting secure access to imaging data and collaboration across institutions, we help researchers and healthcare professionals work together to generate evidences and insights that can contribute to the advancement of healthcare.

This World Stroke Day, we recognise the clinicians, radiologists, researchers, and healthcare teams dedicated to improving our understanding of stroke and advancing care for patients around the world.

💙 Together, let's connect expertise, advance research, and turn imaging into opportunities for discovery.

27/10/2026

Barely unpacked from OCT Nordics, and we are heading to Basel.

This is our first time exhibiting at OCT DACH, 3 and 4 November.
New event for us so we are really looking forward to it.

You will find us at booth 14. Whether you want to discuss an existing study or talk through planning a new one, come and say hello.

26/10/2026

In many of imaging-heavy oncology trials, the reading pool gets built as a single undifferentiated block: “oncology imaging,” staffed by whoever is available with oncology experience.

Mammography doesn’t work that way. BI-RADS is its own classification system, with its own failure modes when a scan gets read by someone trained on CT or MR oncology work instead. A reader who is excellent at RECIST measurements on a chest CT is not automatically equipped to score a mammogram to spec.

The same pattern shows up in rheumatology and MSK endpoints. Joint space narrowing and synovitis scoring call for a different trained eye than a CNS lesion count, even though all three sometimes get folded into one generalist “radiology reads” line item in a protocol.
As more trials specify imaging biomarkers as primary or key secondary endpoints, reader qualification deserves the same scrutiny during protocol design as platform selection, worth raising before the protocol is finalized, not after the first discordant read lands in an adjudication queue.

Read the blog post here: https://eu1.hubs.ly/H0zn23R0

22/10/2026

We are at ESMO in Madrid, this week.

Oncology trials depend on imaging endpoints more than almost any other therapeutic area. Tumour response assessment depends on consistent acquisition across every site, and on blinded central review that holds up to scrutiny. Get that right and the endpoint is solid. Get it wrong and no amount of statistical work later will fix it. That is the conversation we are there for.

From Collective Minds you will find:

Maria Kastenfalk, Director Business Development

Whether you want to discuss imaging in an existing study or talk through planning a new one, let's connect.

20/10/2026

Day one in Copenhagen for OCT Nordics.

Sverre, Maria and Fredrik are at the booth all day. Come by for a coffee and a chat about imaging in clinical trials. Whether you want to discuss an existing study or talk through planning a new one, we are happy to dig into it.

See you at booth 52.

19/10/2026

Today is World Breast Cancer Day

It’s a good moment to pause and recognize how much progress in breast cancer care has come from research, and how much careful work goes into every study behind it.

Imaging plays a quiet but essential role in that work. Scans help research teams decide who can take part in a study, see how tumors respond to treatment and follow results over time. When that imaging is handled well, the questions a study sets out to answer get clearer, more reliable answers.

That’s where we hope to make a difference. At Collective Minds, we support research teams by making the imaging side of their studies run more smoothly, from collecting images at sites to getting them reviewed and keeping track of every case along the way. It’s behind-the-scenes work, but we care about it deeply, because good evidence is what moves treatment forward.

Today we’re thinking of everyone touched by breast cancer, and we’re grateful to be a small part of the research working toward better outcomes. 💗

16/10/2026

Two things usually get treated as a trade-off in imaging trials: moving faster, and producing evidence that holds up.

They are not actually opposed. Most of what slows an imaging trial down is operational, not scientific. Data moved by hand between sites and sponsors. Quality checks that surface weeks after the patient has left. A different portal for every stakeholder. None of it makes the evidence stronger, and all of it costs time and money.

Put the workflow in one place and both problems move at once. Studies run faster and cost less, and the data arrives consistent, traceable and ready for the scrutiny that comes from regulators, investors and partners.

That is what we built Collective Minds to do.

Planning imaging for an upcoming study? Talk to our imaging experts.

Adress

Svärdvägen 5
Danderyd
18322

Telefon

+46705218650

Webbplats

https://www.collectiveminds.health/

Aviseringar

Bli först med att veta: vi skickar ett mejl när Collective Minds publicerar nyheter och kampanjer. Din e-postadress används inte till något annat, och du kan avsluta prenumerationen när som helst.